Holen Sie sich die Stockscreener-App
16.98
4.68%
-0.8606
Schlusskurs vom Vortag:
$17.84
Offen:
$17.4
24-Stunden-Volumen:
165.71K
Relative Volume:
0.05
Marktkapitalisierung:
$1.42B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-15.08M
KGV:
-31.75
EPS:
-0.5348
Netto-Cashflow:
$-32.22M
1W Leistung:
-6.87%
1M Leistung:
-10.78%
6M Leistung:
+176.06%
1J Leistung:
+311.74%
1-Tages-Spanne:
$16.84
$17.60
1-Wochen-Bereich:
$16.84
$18.73
52-Wochen-Spanne:
$2.54
$26.95
Corvus Pharmaceuticals Inc Stock (CRVS) Company Profile
Firmenname
Corvus Pharmaceuticals Inc
Sektor
Branche
Telefon
(650) 900-4520
Adresse
863 MITTEN ROAD, BURLINGAME, CA
Compare CRVS vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRVS
Corvus Pharmaceuticals Inc
|
16.98 | 1.49B | 0 | -15.08M | -32.22M | -0.5348 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.29 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
769.92 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
726.71 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.08 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
294.77 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Corvus Pharmaceuticals Inc Stock (CRVS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-13 | Eingeleitet | Barclays | Overweight |
| 2025-01-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-08-18 | Eingeleitet | Oppenheimer | Outperform |
| 2021-12-01 | Fortgesetzt | Jefferies | Buy |
| 2021-05-27 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-02-10 | Herabstufung | Mizuho | Buy → Neutral |
| 2019-09-12 | Eingeleitet | Mizuho | Buy |
| 2019-05-29 | Eingeleitet | ROTH Capital | Buy |
| 2017-08-24 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2017-05-01 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2016-04-18 | Eingeleitet | Credit Suisse | Outperform |
| 2016-04-18 | Eingeleitet | Guggenheim | Buy |
Alle ansehen
Corvus Pharmaceuticals Inc Aktie (CRVS) Neueste Nachrichten
Market Recap: Is Corvus Pharmaceuticals Inc stock forming a cup and handle2025 Earnings Surprises & Consistent Return Investment Signals - baoquankhu1.vn
Assessing Corvus Pharmaceuticals (CRVS) Valuation After New Soquelitinib Trial Plans And Atopic Dermatitis Data - Sahm
Corvus Pharmaceuticals Highlights Soquelitinib Pipeline, Eyes Phase II Atopic Dermatitis Trial in 2026 - MarketBeat
Corvus Pharmaceuticals at Oppenheimer: Soquelitinib’s Promising Potential By Investing.com - Investing.com Canada
Corvus Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference - Yahoo Finance
Corvus Pharma sets virtual Oppenheimer talk, 90-day replay - Stock Titan
Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Down 7.6%Time to Sell? - MarketBeat
Corvus Pharmaceuticals, Inc. $CRVS Shares Bought by GSA Capital Partners LLP - MarketBeat
Is Corvus Pharmaceuticals (CRVS) Still Attractive After Its Recent Share Price Surge - Yahoo Finance
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Corvus Pharmaceuticals (CRVS) Valuation Check After A Sharp Biotech Share Price Surge - Sahm
Is Corvus Pharmaceuticals (CRVS) Still Attractive After A 185% Monthly Surge? - simplywall.st
Corvus Pharmaceuticals (CRVS) price target increased by 128.26% to 35.70 - MSN
Stock Market Today, Jan. 20: Corvus Pharmaceuticals Surges After Positive Phase 1 Eczema Drug Data - AOL.com
Momentum Is Just Starting for These 3 Rapid-Growth Stocks in 2026 - Investing.com
Commit To Buy Corvus Pharmaceuticals At $8, Earn 20% Using Options - Nasdaq
Momentum Is Just Starting for These 3 Rapid-Growth Stocks in 2026 - The Globe and Mail
CRVS SEC FilingsCorvus Pharmaceu 10-K, 10-Q, 8-K Forms - Stock Titan
Assessing Corvus Pharmaceuticals (CRVS) Valuation After Recent Share Price Momentum - Sahm
Mizuho Raises Price Target on Corvus Pharmaceuticals to $30 From $20, Keeps Outperform Rating - marketscreener.com
Corvus Soquelitinib Data Spurs Phase 2 Plans And Fuels CRVS Reassessment - Sahm
Aug Selloffs: Why is Corvus Pharmaceuticals Inc. stock going downJuly 2025 Price Swings & Accurate Entry/Exit Alerts - mfd.ru
Will Corvus Pharmaceuticals Inc. benefit from rate cutsPrice Action & Low Risk Growth Stock Ideas - mfd.ru
Wall Street Analysts Think Corvus (CRVS) Could Surge 25.29%: Read This Before Placing a Bet - Your Wyoming Link
Corvus Pharmaceuticals Stock Rallies 209% in a Month: Here's Why - Finviz
Corvus Pharmaceuticals (CRVS) Is Up 211.80% in One Week: What You Should Know - Yahoo Finance
10 Big Names Stumbling Hard - Insider Monkey
Corvus Pharmaceuticals (CRVS) Falls on Profit-Taking After 212% Jump - Finviz
Latham Watkins Advises Corvus Pharmaceuticals in Upsized Public Offering of Common Stock - Latham & Watkins LLP
Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Down 9.3%Here's What Happened - MarketBeat
Hedge Fund Moves: Is Corvus Pharmaceuticals Inc exposed to political risk2025 Technical Overview & Consistent Income Trade Recommendations - baoquankhu1.vn
Corvus Pharmaceuticals (CRVS) Soars 212% on Impressive Eczema Therapy Study - Finviz
Why Corvus Pharmaceuticals (CRVS) Is Up 211.8% After Upsized Equity Raise On Soquelitinib Phase 2 Plans - Yahoo Finance
Corvus Pharmaceuticals (CRVS) Valuation Check After Positive Soquelitinib Data And Equity Raise - Sahm
What's Driving the Market Sentiment Around Corvus Pharmaceuticals Inc? - Sahm
Corvus Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $201M - The Manila Times
Corvus Pharmaceuticals raises $201.2 million in upsized public offering By Investing.com - Investing.com South Africa
Corvus rally continues as clinical optimism offsets dilution concerns - Mugglehead Investment Magazine
Corvus Pharmaceuticals raises $201.2 million in upsized public offering - Investing.com
Corvus Pharmaceuticals Closes Upsized Public Offering, Raising Approximately $201.2 Million - Quiver Quantitative
Corvus Pharma raises $201M to support cancer and skin trials - stocktitan.net
Cantor Fitzgerald reiterates Overweight rating on Corvus Pharmaceuticals stock By Investing.com - Investing.com Canada
Corvus Pharmaceuticals (CRVS) Hits All-Time High on Eczema Trial Results - Finviz
Corvus Pharmaceuticals - The Pharma Letter
Corvus Pharmaceuticals Announces Major Underwritten Public Stock Offering - TipRanks
Corvus Pharmaceuticals Announces Public Offering of Common Stock - TradingView
Corvus Pharmaceuticals Shares New Phase I Soquelitinib Data Showing Strong AD EASI Gains - MarketBeat
CRVS Stock Surges Pre-Market After Corvus Expands Equity Raise To $175 Million - Stocktwits
10 Stocks Delivering Double-Digit Gains Effortlessly; 4 Are Hitting New Highs - Insider Monkey
Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Gap UpHere's What Happened - MarketBeat
Jefferies raises Corvus Pharmaceuticals stock price target to $42 on strong AD data - Investing.com Canada
Finanzdaten der Corvus Pharmaceuticals Inc-Aktie (CRVS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.50%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):